Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NT-112
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
NT-112 is an autologous T-cell therapy under development by Neogene Therapeutics (a subsidiary of AstraZeneca) for the treatment of advanced solid tumors, including metastatic non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and endometrial cancer. The therapy consists of autologous T-cells genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR) that specifically targets the KRAS G12D mutation. Additionally, these cells are armored by knocking out the gene encoding transforming growth factor beta receptor type 2 (TGFBR2), making them resistant to immunosuppressive effects mediated by TGF-β in the tumor microenvironment. The product is administered via parenteral infusion following lymphodepletion and concurrent recombinant IL-2 support. Preclinical studies have demonstrated high specificity for KRAS G12D mutant cells and favorable safety and efficacy profiles[1][4][6].
- Other names
- NT 112NT112NT-112
02
Targets
TGFBR2 (TGF-β receptor type 2)KRAS G12D/HLA-C*08:02 (KRAS G12D peptide-HLA-C*08:02 complex)
Beyond the preview
Go deeper on NT-112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NT-112.